Physician profile
Matthew Balanda
NPI 1447651690
$3,338.10
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,098 · 2022: $985 · 2023: $174 · 2024: $81.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $152 · Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $152.14 |
| Food and Beverage | $103.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $1,168.07 | 2021-2022 | |
| Glaxosmithkline, LLC. | $370.16 | 2021-2022 | |
| Pfizer INC. | $299.76 | 2021-2022 | |
| Csl Behring | $227.56 | 2021-2024 | Haegarda, Kcentra |
| Astrazeneca Pharmaceuticals LP | $220.47 | 2021-2023 | Breztri, Farxiga |
| Abbvie INC. | $165.69 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.11 | 2022-2024 | Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.08 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $104.46 | 2021-2022 | |
| Genentech USA, INC. | $102.55 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $77.48 | 2021-2022 | |
| Genzyme Corporation | $60.29 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $58.28 | 2021-2022 | |
| Leo Pharma INC. | $46.23 | 2022 | |
| Optinose US, INC. | $22.47 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $21.02 | 2022 | |
| Covis Pharma Gmbh | $20.08 | 2022 | |
| Kaleo, INC. | $17.89 | 2021 | |
| Phadia US INC. | $14.61 | 2022 | |
| Adma Biomanufacturing LLC | $11.67 | 2021 | |
| Alk-Abello, INC | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Balanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.